Efficacy, safety and tolerability of TD1414 2 percent cream in impetigo and secondarily infected traumatic lesions (SITL).

Trial Profile

Efficacy, safety and tolerability of TD1414 2 percent cream in impetigo and secondarily infected traumatic lesions (SITL).

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2013

At a glance

  • Drugs TD 1414 (Primary) ; Mupirocin
  • Indications Bacterial infections; Impetigo; Wound infections
  • Focus Therapeutic Use
  • Sponsors LEO Pharma
  • Most Recent Events

    • 10 Mar 2010 Actual end date added to 1 Jun 2009 as reported by ClinicalTrials.gov.
    • 10 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 13 Mar 2009 Actual patient number (682) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top